Treament of Spontaneous Tumor Metastases With IL [interleukin]-12 DNA (NSC 709933): A Phase IB Trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tavokinogene telseplasmid (Primary)
- Indications Cancer metastases; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2019 Biomarkers information updated
- 20 Apr 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Sep 2005 New trial record.